Elite Pharmaceuticals Inc (ELTP)

[no2koolaid]

You are absolutely correct and it is apparent because no one has cornered market share while operating with substantial ADF success in the opioid pain med market. It remains that the disruptive tech has yet to be unveiled. Nonetheless, from an empirical perspective, there is nothing in the vast array of patents and successful trials that rejects the potential for Elite to be that disruptive tech. That is not an opinion, it is a practical reality. Moreover, there is a high degree of correlation between firms entering a P-3 trial, completing a P-3 trial and filing an NDA that gets approved. This much is irrefutable. There remains a 90% success rate between those completing a P-3 and having their NDA approved. While some might point out that means there is a 10% chance of failure, I like the odds.